UCB's Global Corporate Website
Welcome to UCB in the United States



Voices on Value: The importance of patient-focused value assessment, Part 1

In order to build a world where care is more accessible to every patient, you have to put patients at the center of everything you do. UCB and The Innovation and Value Initiative (IVI) are focused on developing strategies that make patients the focal point of value assessments. Learn more about our patient centered approach from our Head of U.S. HEOR Strategy, Edward Lee, and IVI Executive Director Jennifer Bright.



UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 



UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab



Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab



UCB Unveils New Data on Living with Myasthenia Gravis at AANEM and MGFA Scientific Exhibit

UCB’s ongoing work and unwavering focus keep people living with MG at the heart of everything we do, and we are committed to finding solutions for rare diseases, like MG, with a high degree of patient need by delivering purposeful innovations and differentiated solutions, creating value that cannot be expressed in numbers alone. 



Paving a Way Forward through Digital Business Transformation

Through UCB’s Digital Business Transformation, we are committed to unleashing the power of digital innovation and enabling solutions that allow patients to live the lives they choose, now and in the future. 



Leaving a Legacy: Alicia Clark Inspires this Hispanic Heritage Month

This Hispanic Heritage Month, we are showcasing the story of Alicia Clark, District Sales Lead, Rheumatology, as it is an inspiration to those around her both inside and outside UCB.



New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress



The Art of Being Data-Enabled: UCB’s Approach to Delivering Innovative Patient Solutions



Connecting Data Insights to Patient Impacts: Imagining the Future of UCB’s Digital Business Transformation (DBT)

Kim Moran, UCB’s U.S. Head of Insights to Impact, is dedicated to UCB’s overall mission of creating value for people living with severe diseases. With an extensive knowledge of data and science, gained during her 14 years at UCB, Kim has put her ability to glean insights from available data to develop solutions that seek to improve the lives of people living with severe diseases.